CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16,390 enrolled
Drug / intervention
BCG-Japan +1 morebiological
Likely dose
BCG-Japan 0.05 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04383925
NCT04383925Phase 4Completed

Randomized Trial Evaluating the Non-specific Effects of Different BCG Strains in Guinea-Bissau: Effects on Early-life Mortality and Morbidity

Bandim Health Project·interventional·Posted May 12, 2020·Updated Jan 22, 2024

In Brief

A Phase 4 clinical trial evaluating BCG-Japan and BCG-Russia for Death, Infant and Morbidity;Infant. Completed, enrolled 16,390 participants across 1 site.

Detailed Summary

The trial will be a two-year outcome assessor-blinded RCT at the maternity ward of hospital Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau to compare BCG-Japan versus BCG-Russia 1:1 in 15,000 infants with respect to mortality, morbidity and case-fatality rate during hospital admission. The trial will also examine the association between BCG strains and BCG skin reaction characteristics by six weeks (data collected by telephone) and at two and six months (data collected at home-visits to a subgroup of the cohort). As a secondary aim, this large study will be used to further evaluate the role of maternal BCG immune priming for overall health, since there are indications that maternal BCG scarring enhances the non-specific effects of BCG.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGuinea-Bissau

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedMay 12, 2020
Enrollment StartMay 4, 2020
Primary CompletionOct 30, 2022
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.1 years ago

Interventions

BCG-Japanbiological

Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).

BCG-Russiabiological

Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)